Article Sidebar
Views PDF: 5
VIÊM PHỔI DO PNEUMOCYSTIS JIROVECII TRÊN NGƯỜI BỆNH GHÉP THẬN: CA LÂM SÀNG VÀ TỔNG QUAN Y VĂN
Main Article Content
Abstract
PNEUMOCYSTIS JIROVECII PNEUMONIEA IN RENAL TRANSPLANT RECIPIENTS: CASE REPORT AND LITERATURE REVIEW
Huynh Ngoc Phuong Thao, Tran Minh Hoang , Bui Thi Hanh Duyen
Pneumocystis Jirovecii pneumonia (PJP) is an opportunistic infection that can occur in kidney transplant patients, especially in the first 6 months after transplantation. PJP is also an important cause of death in kidney transplant patients. We report two cases of PJP in kidney transplant patients treated at the University Medical Center of Ho Chi Minh City (UMC). The first patient received a kidney transplant at UMC, this is the first case of PJP complications recorded at our center. In this case, PJP occurred about 2,5 months after transplantation, with vague clinical symptoms and severe lung injury on chest X-ray. In the second case, the patient had a kidney transplant at another center, PJP occurred relatively late, up to 4 years after the kidney transplant. In this case, his first complaint was not respiratory symptoms but unexplained weight loss. Both cases of PJP were severe, the patients were referred for follow-up in the Intensive Care Unit. Both responded well to treatment and were discharged with fully recovered respiratory status.
Article Details
Keywords
Pneumocystis jirovecii pneumonia, opportunistic infection, kidney transplant recipient, immunosuppression
References
2. Santos CA, Brennan DC, Saeed MJ, Fraser VJ, Olsen MA. Pharmacoepidemiology of cytomegalovirus prophylaxis in a large retrospective cohort of kidney transplant recipients with Medicare Part D coverage. Clinical transplantation. Apr 2016; 30(4):435-444. DOI:10.1111/ ctr.12706.
3. Prasad P, Lo KB, Ram P. Late presentation of Pneumocystis jirovecii pneumonia after renal transplant: A case report. Medical mycology case reports. Jun 2018; 20:33-34. DOI:10.1016/j.mmcr.2018.01.006.
4. Maini R, Henderson KL, Sheridan EA, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerging infectious diseases. Mar 2013; 19(3):386-392. DOI:10.3201/eid1903.121151.
5. Fillatre P, Decaux O, Jouneau S, et al. Incidence of Pneumocystis jiroveci pneumonia among groups at risk in HIV-negative patients. The American journal of medicine. Dec 2014; 127(12):1242.e11-7. DOI:10.1016/ j.amjmed.2014.07.010.
6. Fishman JA, Gans H. Pneumocystis jiroveci in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clinical transplantation. Sep 2019; 33(9):e13587. DOI:10.1111/ctr.13587.
7. Kim JE, Han A, Lee H, Ha J, Kim YS, Han SS. Impact of Pneumocystis jirovecii pneumonia on kidney transplant outcome. BMC nephrology. Jun 10 2019; 20(1):212. DOI:10.1186/s12882-019-1407-x.
8. Tasaka S, Hasegawa N, Kobayashi S, et al. Serum indicators for the diagnosis of pneumocystis pneumonia. Chest. Apr 2007; 131(4):1173-1180. DOI:10.1378/chest.06-1467.
9. Kales CP, Murren JR, Torres RA, Crocco JA. Early predictors of in-hospital mortality for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. Archives of internal medicine. Aug 1987; 147(8):1413-1417.
10. Tasaka S. Recent Advances in the Diagnosis and Management of Pneumocystis Pneumonia. Tuberculosis and respiratory diseases. Apr 2020; 83(2):132-140. DOI:10.4046/trd.2020. 0015.